Apolipoprotein E genotype modulates the effect of black tea drinking on blood lipids and blood coagulation factors: A pilot study

British Journal of Nutrition

Volumn 79, Issue 2, 1998, Pages 133-139

  Loktionov, Alexandre ^a   Bingham, Sheila A ^a   Vorster, Hester ^b   Jerling, Johann C ^b   Runswick, Shirley A ^a   Cummings, John H ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b NORTH WEST UNIVERSITY   (South Africa)

Author keywords

Apolipoproteins; Cardiovascular disease; Dietary intervention; Genotype; Tea

Indexed keywords

APOLIPOPROTEIN E; BLOOD CLOTTING FACTOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CAUCASIAN; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; HUMAN EXPERIMENT; LIPID BLOOD LEVEL; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; TEA;

ADULT; AGED; APOLIPOPROTEINS E; BLOOD COAGULATION FACTORS; CARDIOVASCULAR DISEASES; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIET; FEMALE; GENOTYPE; HUMANS; LIPIDS; MALE; MIDDLE AGED; PILOT PROJECTS; PLASMINOGEN ACTIVATOR INHIBITOR 1; RISK FACTORS; TEA; TRIGLYCERIDES;

EID: 0031917358     PISSN: 00071145     EISSN: None     Source Type: Journal    
DOI: 10.1079/BJN19980024     Document Type: Article

References (34)

1. Bingham SA, Vorster H, Jerling JC, Magee E, Mulligan A, Runswick SA & Cummings JH (1997) Effect of black tea drinking on blood lipids, blood pressure and aspects of bowel habit. British Journal of Nutrition 78, 41-55.
2. Bredie SJH, Vogelaar JM, Demacker PNM & Stalenhoef AFH (1996) Apolipoprotein E polymorphism influences lipid phenotypic expression, but not the low density lipoprotein subfraction distribution in familial combined hyperlipidemia. Atherosclerosis 126, 313-324.
3. Bu GJ, Maksymovitch EA, Nerbonne JM & Schwartz AL (1994) Expression and function of low-density lipoprotein receptor-related protein (LRP) in mammalian central neurons. Journal of Biological Chemistry 269, 18521-18528.
4. Castelli WP (1996) Lipids, risk factors and ischaemic heart disease. Atherosclerosis 124 Suppl., S1-S9.
5. Clauss A (1957) Gerinnungsphysiologissche Schellmetode zur Bestimmung des Fibrinogens (A quick fibrinogen determination method based on clotting physiology). Acta Haematologica 17, 237-246.
6. Dammerman M & Breslow JL (1995) Genetic basis of lipoprotein disorders. Circulation 91, 505-512.
7. Davignon J, Cregg RE & Sing CF (1988) Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 9, 405-411.
8. Department of Health (1994) Nutritional Aspects of Cardiovascular Disease. Report on Health and Social Subjects no. 46. London: H.M. Stationery Office.
9. Hamsten A, De Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blombäck, M & Wiman B (1987) Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet ii, 3-8.
10. Hixson JE & Vernier DT (1990) Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. Journal of Lipid Research 31, 545-548.
11. Jansen JWCM & Reinders JH (1992) Fibrinolysis: system and processes. Coronary Artery Disease 3, 425-434.
12. Juhan-Vague I & Alessi MC (1997) PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thrombosis and Haemostasis 78, 656-660.
13. Kamboh MI, Aston CE & Hamman RF (1995) The relationship of APOE polymorphism and cholesterol levels in normoglycemic and diabetic subjects in a biethnic population from the San Luis Valley, Colorado. Atherosclerosis 112, 145-159.
14. Kannel WB, Wolf PA, Castelli WP & D'Agostino RB (1987) Fibrinogen and risk of cardiovascular disease. The Framingham study. Journal of the American Medical Association 258, 1183-1186.
15. Kontula K, Aalto-Setälä K, Kuusi T, Hämäläinen L & Syvänen A-C (1990) Apolipoprotein E polymorphism determined by restriction enzyme analysis of DNA amplified by polymerase chain reaction: convenient alternative to phenotyping by isoelectric focusing. Clinical Chemistry 36, 2087-2092.
16. Mahley RW (1988) Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 240, 622-630.
17. Manttari M, Koskinen P, Enholm C, Huttunen JK & Manninen V (1991) Apolipoprotein E polymorphism influences the serum cholesterol response to dietary intervention. Metabolism 40, 217-221.
18. Marshall JA, Kamboh MI, Bessesen DH, Hoag S, Hamman RF & Ferrell RE (1996). Associations between dietary factors and serum lipids by apolipoprotein E polymorphism. American Journal of Clinical Nutrition 63, 87-95.
19. Nakata Y, Katsaya T, Rakugi H, Takami S, Ohishi H, Kamino K, Higaki J, Tabuchi Y, Kimahara Y, Miki T & Ogihara T (1996) Polymorphism of the apolipoprotein-E and angiotensinconverting enzyme genes in Japanese subjects with silent myocardial ischemia. Hypertension 27, 1205-1209.
20. Nilsson TK, Sundell IB, Hellsten G & Hallmans G (1990) Reduced plasminogen activator inhibitor activity in high consumers of fruits, vegetables and root vegetables. Journal of Internal Medicine 227, 267-271.
21. Olofsson BO, Dahlen G & Nilsson TK (1989) Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease. European Heart Journal 10, 77-82.
22. Paik Y-K, Chang DJ, Reardon CA, Davies GE, Mahley RW & Taylor JM (1985). Nucleotide sequence and structure of the human apolipoprotein E gene. Proceedings of the National Academy of Sciences USA 82, 3445-3449.
23. Paramo JA, Colucci M, Collen D & van de Werf F (1985) Plasminogen activator inhibitor in the blood of patients with coronary heart disease. Lancet 291, 573-574.
24. Patsch JR (1993) Is hypertriglyceridemia atherogenic? Atherosclerosis Reviews 25, 331-339.
25. Rebeck GW, Harr SD, Strickland DK & Hyman BT (1995) Multiple, diverse senile plaque-associated proteins are ligands of an apolipoprotein E receptor, the Alpha(2)-macroglobulin receptor low-density-lipoprotein receptor protein. Annals of Neurology 37, 211-217.
26. Routi T, Rönnemaa T, Salo P, Seppänen R, Marniemi J, Viikari J, Enholm C & Simell O (1996) Effects of prospective, randomized cholesterol-lowering dietary intervention and apolipoprotein E phenotype on serum lipoprotein(a) concentrations of infants aged 7-24 mo. American Journal of Clinical Nutrition 63, 386-391.
27. Schächter F, Faure-Delanef L, Guénot F, Rouger H, Froguel P, Lesueur-Ginot L & Cohen D (1994) Genetic associations with human longevity at the APOE and ACE loci. Nature Genetics 6, 29-32.
28. Scheer WD, Boudreau DA, Malcolm GT & Middaugh JP (1995) Apolipoprotein E and atherosclerosis in Alaska Natives. Atherosclerosis 114, 197-202.
29. Vorster H, Jerling J, Oosthuizen W, Cummings J, Bingham S, Magee L, Mulligan A & Runswick S (1996) Tea drinking and haemostasis: a randomised, placebo controlled, cross over study in free living subjects. Haemostasis 26, 58-64.
30. Weisgraber KH & Mahley RW (1996) Human apolipoprotein E: the Alzheimer's disease connection. FASEB Journal 10, 1485-1494.
31. Wenham PR, Price WH & Blundell G (1991) Apolipoprotein E genotyping by one-stage PCR. Lancet 337, 1158-1159.
32. Wilson PF, Myers RH, Larson MG, Ordovas JM, Wolf PA & Schaefer EJ (1994) Apolipoprotein E alleles, dyslipidemia and coronary heart disease. The Framingham Offspring Study. Journal of the American Medical Association 272, 1666-1671.
33. Wilson PWF, Schaeffer EJ, Larson MG & Ordovas JM (1996) Apolipoprotein-E alleles and risk of coronary disease - a metaanalysis. Arteriosclerosis, Thrombosis and Vascular Biology 16, 1250-1255.
34. Xu CF, Boerwinkle E, Tikkanen MJ, Huttunen JK & Manninen V (1990) Genetic variation at the apolipoprotein loci contribute to response of plasma lipids to dietary change. Genetic Epidemiology 7, 261-275.